CG
CTMX icon

Cutler Group’s CytomX Therapeutics CTMX Stock Holding History

Cutler Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$1K – 2494
2023
Q4 		$1K Hold
1,000
– – ﹤0.01% 3292
2023
Q3 		$1K Hold
1,000
– – ﹤0.01% 3459
2023
Q2 		$1K Hold
1,000
– – ﹤0.01% 3220
2023
Q1 		$1K Sell
1,000
-200
-17% -$452 ﹤0.01% 3372
2022
Q4 		$1K Hold
1,200
– – ﹤0.01% 3959
2022
Q3 		$1K Hold
1,200
– – ﹤0.01% 4473
2022
Q2 		$2K Hold
1,200
– – ﹤0.01% 4251
2022
Q1 		$3K Hold
1,200
– – ﹤0.01% 4425
2021
Q4 		$5K Hold
1,200
– – ﹤0.01% 4162
2021
Q3 		$6K Hold
1,200
– – ﹤0.01% 4312
2021
Q2 		$7K Buy
1,200
+700
+140% +$5.45K ﹤0.01% 4170
2021
Q1 		$3K Hold
500
– – ﹤0.01% 4667
2020
Q4 		$3K Sell
500
-600
-55% -$4.29K ﹤0.01% 3920
2020
Q3 		$7K Buy
1,100
+900
+450% +$6.67K ﹤0.01% 3228
2020
Q2 		$1K Sell
200
-100
-33% -$929 ﹤0.01% 3987
2020
Q1 		$2K Hold
300
– – ﹤0.01% 3452
2019
Q4 		$2K Hold
300
– – ﹤0.01% 3414
2019
Q3 		$2K Hold
300
– – ﹤0.01% 3456
2019
Q2 		$3K Sell
300
-700
-70% -$7.34K ﹤0.01% 3344
2019
Q1 		$10K Hold
1,000
– – ﹤0.01% 2477
2018
Q4 		$15K Buy
+1,000
New +$14.8K ﹤0.01% 2297
2018
Q3 		– Sell
-100
Closed -$2.28K – 4180
2018
Q2 		$2K Buy
+100
New +$2.55K ﹤0.01% 3536
2018
Q1 		– Sell
-500
Closed -$14.3K – 4569
2017
Q4 		$10K Buy
+500
New +$10.4K ﹤0.01% 3109

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cutler Group's CTMX Position: Q1 2024 in Review

Cutler Group sold out of CytomX Therapeutics (CTMX) in Q1 2024, closing a stake of 1,000 shares — an estimated $1K sold.

Cutler Group first reported a position in CTMX in Q4 2017 and held it in 23 quarters. The position peaked at $15K in Q4 2018. 88 funds tracked by Wall St. Rank hold CTMX as of Q1 2024.

  • Cutler Group reported no remaining CytomX Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1,000 CytomX Therapeutics shares in Q1 2024, an estimated $1K.
  • Cutler Group first reported a position in CytomX Therapeutics in Q4 2017 and held it in 23 quarters.
  • Cutler Group's CytomX Therapeutics position peaked at $15K in Q4 2018.
  • 88 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.